Overview

Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients.

Status:
Completed

Trial end date:
2009-01-01

Target enrollment:
0

Participant gender:
All

Summary

To compare the effect of insulin sensitizing drugs (metformin and rosiglitazone) over glucose homeostasis (GH) in no diabetic metabolic syndrome individuals. A randomized blinded clinical trial did in patients with metabolic syndrome (n=30), without diabetes. Prior to detailed information and signature of informed consent by patients were done three treatment groups by randomized technique; a) Placebo, b) Metformin (850 mg/day), c) Rosiglitazone (4 mg/day), treatment was administered for 8 weeks. GH was measured before and after treatment using oral glucose tolerance test (OGTT), and IR-index (Homeostatic Model). Determination was performed on weight, size, body mass index, plicometry, blood pressure, fasting glucose levels, triglycerides, HDL-cholesterol and insulin.

Phase:

Phase 2/Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

J JESUS VENEGAS, MD

Collaborators:

Instituto Mexicano del Seguro Social
National Council of Science and Technology, Mexico

Treatments:

Metformin
Rosiglitazone

Criteria

Inclusion Criteria:

- > 18 years old.

- Metabolic Syndrome criteria of World Health Organization .

Exclusion Criteria:

- Diabetes Mellitus

- Allergic to Metformin,

- Allergic to rosiglitazone.

- Hepatic disease.

- Hearth disease.